Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

Inclusion Criteria: * male and female adult patients with clinical diagnosis of bronchial asthma or chronic obstructive pulmonary disease * patients on regular medication with inhaled corticosteroids and long-acting beta-2-agonists in fixed-dose combination * patients who recently changed medication to DuoResp® Spiromax or are about to do so * capacitated person with present declaration of consent Exclusion Criteria: * diseases contraindicated in accordance with the summary of product characteristic * patients who take part in interventional clinical trials parallel or during the last 4 weeks * patient shows conditions or diseases that might disturb the monitoring according to the physician * patients with substance misuse in their case history (drugs, alcohol) or with other factors (e.g. serious psychiatric conditions) that limit their ability to participate in the study * insufficient German language knowledge to understand the patient education and to complete the questionnaires in a correct manner * patients involved in the planning and construction of the study (Teva staff and employees of the centres) * patient is incapable of giving consent